CA2964625C - Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists - Google Patents

Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists Download PDF

Info

Publication number: CA2964625C
Authority: CA; Canada
Prior art keywords: compound; liver disease; fatty liver; receptor; formula
Prior art date: 2014-10-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

CA2964625A

Other languages

English (en)

French (fr)

Other versions

CA2964625A1 (en

Inventor

Joseph K. Belanoff

Hazel Hunt

Onno C. MEIJER

Jose VAN DEN HEUVEL

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Corcept Therapeutics Inc

Original Assignee

Corcept Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-15

Filing date

2015-10-14

Publication date

2023-03-07

2015-10-14 Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc

2016-04-21 Publication of CA2964625A1 publication Critical patent/CA2964625A1/en

2023-03-07 Application granted granted Critical

2023-03-07 Publication of CA2964625C publication Critical patent/CA2964625C/en

Status Active legal-status Critical Current

2035-10-14 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA2964625A 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists Active CA2964625C (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201462064358P	2014-10-15	2014-10-15
US62/064,358		2014-10-15
US201462092041P	2014-12-15	2014-12-15
US62/092,041		2014-12-15
PCT/US2015/055487 WO2016061195A1 (en)	2014-10-15	2015-10-14	Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Publications (2)

Publication Number	Publication Date
CA2964625A1 CA2964625A1 (en)	2016-04-21
CA2964625C true CA2964625C (en)	2023-03-07

Family

ID=55747256

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2964625A Active CA2964625C (en)	2014-10-15	2015-10-14	Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Country Status (22)

Country	Link
US (5)	US10238659B2 (2)
EP (2)	EP4353310A3 (2)
JP (1)	JP6761410B2 (2)
KR (1)	KR102435956B1 (2)
CN (2)	CN107106562B (2)
AU (1)	AU2015333645B2 (2)
BR (1)	BR112017007860B1 (2)
CA (1)	CA2964625C (2)
DK (1)	DK3206692T3 (2)
ES (1)	ES2978871T3 (2)
FI (1)	FI3206692T3 (2)
IL (1)	IL251729B (2)
MX (1)	MX2017004943A (2)
NZ (1)	NZ731060A (2)
PH (1)	PH12017500710B1 (2)
PL (1)	PL3206692T3 (2)
PT (1)	PT3206692T (2)
RU (1)	RU2718921C2 (2)
SG (1)	SG11201703024VA (2)
UA (1)	UA123537C2 (2)
WO (1)	WO2016061195A1 (2)
ZA (1)	ZA201702813B (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG11201703024VA (en)	2014-10-15	2017-05-30	Corcept Therapeutics Inc	Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
CA3102099C (en)	2018-06-04	2023-09-26	Corcept Therapeutics Incorporated	Pyrimidine cyclohexenyl glucocorticoid receptor modulators
AU2020239920A1 (en)	2019-03-18	2021-11-04	Arnold L. Newman	Method of improving insulin sensitivity
CA3182272A1 (en) *	2020-05-06	2021-11-11	Corcept Therapeutics Incorporated	Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
WO2021226258A1 (en) *	2020-05-06	2021-11-11	Corcept Therapeutics Incorporated	Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102481705B1 (ko) *	2020-08-04	2022-12-27	연세대학교 산학협력단	트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
MX2023007403A (es) *	2020-12-21	2023-08-16	Corcept Therapeutics Inc	Método de preparación de los moduladores del receptor de ciclohexilo de pirimidina glucocorticoides.
CA3217413A1 (en) *	2021-05-05	2022-11-10	Ada Lee	Methods for reducing liver fat and for treating fatty liver disorders
WO2025174745A1 (en) *	2024-02-12	2025-08-21	Corcept Therapeutics Incorporated	MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS
WO2025255357A1 (en) *	2024-06-06	2025-12-11	Corcept Therapeutics Incorporated	Methods for preparing and maintaining livers and portions thereof for liver transplantation
EP4732836A1 (en)	2024-10-22	2026-04-29	Consejo Superior De Investigaciones Científicas	Ag5 compound for use in the treatment of in fatty liver diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2153546A (en)	1936-07-29	1939-04-11	Universal Draft Gear Attachmen	Hand brake actuating mechanism
US4391904A (en)	1979-12-26	1983-07-05	Syva Company	Test strip kits in immunoassays and compositions therein
GB0213745D0 (en) *	2002-06-14	2002-07-24	Univ Edinburgh	Enzyme
EP1534273A4 (en)	2002-07-18	2007-08-22	Bristol Myers Squibb Co	MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD
WO2006124710A1 (en)	2005-05-18	2006-11-23	Merck & Co., Inc.	D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands
US8389472B2 (en) *	2005-08-19	2013-03-05	Amylin Pharmaceuticals, Llc	Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
KR20080065617A (ko) *	2005-09-19	2008-07-14	존슨 앤드 존슨 파머슈티컬 리서치 앤드 디벨로프먼트 엘엘씨	글루코코티코이드 수용체 발현의 조절
GB0601092D0 (en) *	2006-01-19	2006-03-01	Daniolabs Ltd	The Prevention Of Systemic Side-Effects Of Glucocorticoids
SI2032134T1 (sl)	2006-05-09	2015-10-30	Genzyme Corporation	Postopki zdravljenja bolezni zamaščenih jeter, ki obsegajo inhibicijo sintezo glukosfingolipida
US9623021B2 (en)	2007-01-22	2017-04-18	Gtx, Inc.	Nuclear receptor binding agents
WO2008127591A2 (en)	2007-04-13	2008-10-23	Schering Corporation	Pyrimidinedione derivatives and use thereof
US8003689B2 (en)	2008-06-20	2011-08-23	Gtx, Inc.	Metabolites of selective androgen receptor modulators and methods of use thereof
MY172424A (en)	2009-04-03	2019-11-25	Hoffmann La Roche	Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
DK2685827T3 (en) *	2011-03-18	2016-05-17	Corcept Therapeutics Inc	PYRIMIDIN -cyclohexyl- glucocorticoid receptor MODULATORS
SG11201703024VA (en)	2014-10-15	2017-05-30	Corcept Therapeutics Inc	Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

2015
- 2015-10-14 SG SG11201703024VA patent/SG11201703024VA/en unknown
- 2015-10-14 BR BR112017007860-0A patent/BR112017007860B1/pt active IP Right Grant
- 2015-10-14 RU RU2017114596A patent/RU2718921C2/ru active
- 2015-10-14 US US14/883,369 patent/US10238659B2/en active Active
- 2015-10-14 PT PT158512384T patent/PT3206692T/pt unknown
- 2015-10-14 CA CA2964625A patent/CA2964625C/en active Active
- 2015-10-14 MX MX2017004943A patent/MX2017004943A/es active IP Right Grant
- 2015-10-14 EP EP24157529.9A patent/EP4353310A3/en active Pending
- 2015-10-14 CN CN201580068262.4A patent/CN107106562B/zh active Active
- 2015-10-14 ES ES15851238T patent/ES2978871T3/es active Active
- 2015-10-14 WO PCT/US2015/055487 patent/WO2016061195A1/en not_active Ceased
- 2015-10-14 EP EP15851238.4A patent/EP3206692B1/en active Active
- 2015-10-14 PL PL15851238.4T patent/PL3206692T3/pl unknown
- 2015-10-14 FI FIEP15851238.4T patent/FI3206692T3/fi active
- 2015-10-14 UA UAA201704069A patent/UA123537C2/uk unknown
- 2015-10-14 PH PH1/2017/500710A patent/PH12017500710B1/en unknown
- 2015-10-14 CN CN202010597452.8A patent/CN111557942B/zh active Active
- 2015-10-14 DK DK15851238.4T patent/DK3206692T3/da active
- 2015-10-14 KR KR1020177012950A patent/KR102435956B1/ko active Active
- 2015-10-14 JP JP2017520388A patent/JP6761410B2/ja active Active
- 2015-10-14 NZ NZ731060A patent/NZ731060A/en unknown
- 2015-10-14 AU AU2015333645A patent/AU2015333645B2/en active Active
2017
- 2017-04-13 IL IL251729A patent/IL251729B/en active IP Right Grant
- 2017-04-21 ZA ZA2017/02813A patent/ZA201702813B/en unknown
2019
- 2019-01-24 US US16/256,295 patent/US10881660B2/en active Active
2020
- 2020-12-03 US US17/111,288 patent/US11590135B2/en active Active
2023
- 2023-01-26 US US18/101,986 patent/US12226417B2/en active Active
2025
- 2025-01-09 US US19/014,779 patent/US20250221995A1/en active Pending

Also Published As

Publication number	Publication date
JP6761410B2 (ja)	2020-09-23
AU2015333645B2 (en)	2020-01-30
AU2015333645A1 (en)	2017-05-04
PL3206692T3 (pl)	2024-07-22
US20210085682A1 (en)	2021-03-25
CN111557942B (zh)	2023-10-03
CN111557942A (zh)	2020-08-21
KR20170066646A (ko)	2017-06-14
KR102435956B1 (ko)	2022-08-23
RU2718921C2 (ru)	2020-04-15
US10238659B2 (en)	2019-03-26
RU2017114596A (ru)	2018-11-15
US20230218621A1 (en)	2023-07-13
JP2017531013A (ja)	2017-10-19
PT3206692T (pt)	2024-04-30
IL251729B (en)	2020-03-31
IL251729A0 (en)	2017-06-29
BR112017007860A2 (pt)	2018-01-16
FI3206692T3 (fi)	2024-05-06
PH12017500710A1 (en)	2017-10-09
BR112017007860B1 (pt)	2023-03-07
EP3206692A4 (en)	2018-05-30
SG11201703024VA (en)	2017-05-30
US10881660B2 (en)	2021-01-05
US20250221995A1 (en)	2025-07-10
UA123537C2 (uk)	2021-04-21
ES2978871T3 (es)	2024-09-23
CN107106562B (zh)	2020-08-18
EP4353310A3 (en)	2024-06-19
CA2964625A1 (en)	2016-04-21
US11590135B2 (en)	2023-02-28
DK3206692T3 (da)	2024-04-29
US12226417B2 (en)	2025-02-18
US20190151318A1 (en)	2019-05-23
MX2017004943A (es)	2017-07-19
EP3206692B1 (en)	2024-04-03
US20160106749A1 (en)	2016-04-21
ZA201702813B (en)	2019-05-29
WO2016061195A1 (en)	2016-04-21
EP4353310A2 (en)	2024-04-17
PH12017500710B1 (en)	2024-01-17
CN107106562A (zh)	2017-08-29
EP3206692A1 (en)	2017-08-23
RU2017114596A3 (2)	2019-05-08
NZ731060A (en)	2023-07-28

Legal Events

Date	Code	Title	Description
2020-06-22	EEER	Examination request	Effective date: 20200529
2024-09-05	MPN	Maintenance fee for patent paid	Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9
2024-09-05	U00	Fee paid	Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240905
2024-09-05	U11	Full renewal or maintenance fee paid	Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240905 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240905
2025-09-02	MPN	Maintenance fee for patent paid	Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10
2025-09-02	U00	Fee paid	Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250902
2025-09-02	U11	Full renewal or maintenance fee paid	Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250902

Publication	Publication Date	Title
US12226417B2 (en)	2025-02-18	Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
CN103596431B (zh)	2016-06-22	嘧啶环己基糖皮质激素受体调节剂
Mejia et al.	2012	Evaluation and differential diagnosis of marked, persistent eosinophilia
Dragovic et al.	2016	Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man
WO2006074428A2 (en)	2006-07-13	Cxcr4 antagonists for the treatment of medical disorders
US12263169B2 (en)	2025-04-01	Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
KR20180116372A (ko)	2018-10-24	체크포인트 억제제를 강화시키기 위한 글루코코르티코이드 수용체 조정제의 용도
HK40102771A (en)	2024-06-14	Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
HK1240087B (zh)	2021-04-30	使用糖皮質激素和鹽皮質激素受體拮抗劑的脂肪肝疾病治療
HK1240087A1 (en)	2018-05-18	Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
JP2009073836A (ja)	2009-04-09	新規なチューブリン重合阻害物質：ベンゾイルフェニル尿素（ｂｐｕ）硫黄類似体の設計及び合成
BR112018067330B1 (pt)	2025-05-27	Uso de moduladores de receptor de glicocorticoide para potencializar inibidores de sinalização